ANKRD39: A Potential Drug Target and Biomarker (G51239)

Target Name: ANKRD39

NCBI ID: G51239

ANKRD39

Other Name(s): Ankyrin repeat domain-containing protein 39 | ankyrin repeat domain 39 | Ankyrin repeat domain 39 | ANR39_HUMAN

ANKRD39: A Potential Drug Target and Biomarker

Ankyrin repeat domains are a type of gene expression factor that have been identified in a variety of organisms, including humans. These domains are characterized by the repeated sequence of the amino acid cysteine, which is known for its ability to form a covalent bond with a carbon atom. One such domain, ANKRD39, has been identified as a potential drug target and biomarker in various diseases.

The ANKRD39 protein is a 22 kDa protein that is expressed in various tissues and organs, including the brain, heart, liver, and muscle. It is characterized by the presence of ankyrin repeating units, which is a conserved region that is found in various proteins that are involved in a variety of cellular processes, including signaling pathways, DNA replication, and protein-protein interactions.

The ANKRD39 protein is involved in several signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival. The TGF-β pathway is a complex signaling pathway that is involved in the regulation of cellular processes that are critical for tissue growth, repair, and regeneration. ANKRD39 has been shown to be involved in the regulation of TGF-β signaling by modulating the activity of the transcription factor SMAD.

In addition to its involvement in TGF-β signaling, ANKRD39 has also been shown to be involved in several other signaling pathways, including the PI3K/AKT signaling pathway, which is involved in the regulation of cellular processes that are critical for survival and metabolism. The PI3K/AKT signaling pathway is a signaling pathway that is involved in the regulation of protein-protein interactions, as well as the regulation of cell adhesion and migration. ANKRD39 has been shown to be involved in the regulation of PI3K/AKT signaling by modulating the activity of the protein PDGFR.

The ANKRD39 protein is also involved in the regulation of several cellular processes that are critical for maintaining cellular homeostasis. For example, ANKRD39 has been shown to be involved in the regulation of ion homeostasis, as well as the regulation of protein synthesis and degradation.

In addition to its involvement in several signaling pathways, ANKRD39 has also been shown to be involved in the regulation of cellular processes that are critical for tissue repair and regeneration. For example, ANKRD39 has been shown to be involved in the regulation of cell proliferation, as well as the regulation of cell survival and migration.

As a potential drug target, ANKRD39 has been shown to have a number of potential therapeutic applications. For example, ANKRD39 has been shown to be involved in the regulation of TGF-β signaling, which is involved in the regulation of cellular processes that are critical for tissue growth, repair, and regeneration. Therefore, ANKRD39 may be an attractive target for drugs that are designed to promote tissue growth, repair, and regeneration.

In addition to its potential therapeutic applications, ANKRD39 has also been shown to be involved in the regulation of several cellular processes that are critical for maintaining cellular homeostasis. Therefore, ANKRD39 may also be an attractive target for drugs that are designed to regulate cellular homeostasis.

Overall, ANKRD39 is a protein that has been shown to be involved in several signaling pathways that are critical for cellular processes. As a potential drug target, ANKRD39 has the potential to be an effective therapy for a variety of diseases. Additionally, ANKRD39 can also be used as a biomarker to diagnose diseases.

Protein Name: Ankyrin Repeat Domain 39

The "ANKRD39 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD39 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets